As of Feb 05
| +0.25 / +2.14%|
The 7 analysts offering 12-month price forecasts for Nektar Therapeutics have a median target of 19.00, with a high estimate of 21.00 and a low estimate of 14.00. The median estimate represents a +59.13% increase from the last price of 11.94.
The current consensus among 7 polled investment analysts is to Buy stock in Nektar Therapeutics. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.